SG11201903012RA - Anti-c1s antibodies and methods of use thereof - Google Patents
Anti-c1s antibodies and methods of use thereofInfo
- Publication number
- SG11201903012RA SG11201903012RA SG11201903012RA SG11201903012RA SG11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA SG 11201903012R A SG11201903012R A SG 11201903012RA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- antibodies
- present disclosure
- disclosure provides
- san francisco
- Prior art date
Links
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 230000024203 complement activation Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
WO 18/07 167 6 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 19 April 2018 (19.04.2018) WIP0 1 PCT omit VIII °nolo mom VIII ioo mom° oimIE (10) International Publication Number WO 2018/071676 Al (51) International Patent Classification: A01N 1/02 (2006.01) A61K 39/395 (2006.01) A61B 5/055 (2006.01) (21) International Application Number: PCT/US2017/056349 (22) International Filing Date: 12 October 2017 (12.10.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/407,390 12 October 2016 (12.10.2016) US (71) Applicant: BIOVERATIV USA INC. [US/US]; 951 Gate- way Blvd., South San Francisco, CA 94080 (US). (72) Inventors: PANICKER, Sandip; 951 Gateway Boulevard, South San Francisco, CA 94080 (US). PARRY, Graham; 951 Gateway Boulevard, South San Francisco, CA 94080 (US). STAGLIANO, Nancy, E.; 951 Gateway Boulevard, South San Francisco, CA 94080 (US). (74) Agent: KIM, Ji-Eun et al.; Sterne, Kessler, Goldstein & Fox P.L.L.C., 1100 New York Avenue, NW, Washington, DC 20005 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF (57) : The present disclosure provides antibodies that specifically bind complement pathway component Cls. The present disclosure provides nucleic acids comprising nucleotide sequences encoding the anti-Cls antibodies; and host cells comprising the nu- cleic acids. The present disclosure provides compositions comprising the anti-Cls antibodies. The present disclosure provides methods of use of the anti-Cls antibodies.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662407390P | 2016-10-12 | 2016-10-12 | |
| PCT/US2017/056349 WO2018071676A1 (en) | 2016-10-12 | 2017-10-12 | Anti-c1s antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201903012RA true SG11201903012RA (en) | 2019-05-30 |
Family
ID=61906346
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201903012RA SG11201903012RA (en) | 2016-10-12 | 2017-10-12 | Anti-c1s antibodies and methods of use thereof |
Country Status (32)
| Country | Link |
|---|---|
| US (2) | US20200048332A1 (en) |
| EP (2) | EP4652926A2 (en) |
| JP (3) | JP7069138B2 (en) |
| KR (2) | KR102638884B1 (en) |
| CN (2) | CN110300520B (en) |
| AR (1) | AR110677A1 (en) |
| AU (3) | AU2017341766A1 (en) |
| BR (1) | BR112019007309A2 (en) |
| CA (1) | CA3040253A1 (en) |
| CL (1) | CL2019000975A1 (en) |
| CO (1) | CO2019004741A2 (en) |
| CR (1) | CR20190223A (en) |
| DK (1) | DK3525583T3 (en) |
| DO (1) | DOP2019000085A (en) |
| EA (1) | EA201990884A1 (en) |
| EC (1) | ECSP19033211A (en) |
| ES (1) | ES3049257T3 (en) |
| FI (1) | FI3525583T3 (en) |
| HR (1) | HRP20251304T1 (en) |
| IL (2) | IL308156A (en) |
| LT (1) | LT3525583T (en) |
| MX (2) | MX2019004259A (en) |
| MY (1) | MY198182A (en) |
| PE (1) | PE20191031A1 (en) |
| PH (1) | PH12019500789A1 (en) |
| PT (1) | PT3525583T (en) |
| RS (1) | RS67326B1 (en) |
| SG (1) | SG11201903012RA (en) |
| TN (1) | TN2019000109A1 (en) |
| TW (3) | TWI846007B (en) |
| WO (1) | WO2018071676A1 (en) |
| ZA (1) | ZA201902247B (en) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110818798A (en) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | Anti-complement C1s antibodies and uses thereof |
| RS63212B1 (en) | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | ANTI-COMPLEMENT C1S ANTIBODIES AND THEIR APPLICATIONS |
| HUE061076T2 (en) | 2015-04-06 | 2023-05-28 | Bioverativ Usa Inc | Application procedures for humanized anti-C1s antibodies |
| DK3525583T3 (en) | 2016-10-12 | 2025-10-27 | Bioverativ Usa Inc | ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF |
| EP4640703A2 (en) | 2017-11-14 | 2025-10-29 | Chugai Seiyaku Kabushiki Kaisha | Anti-c1s antibodies and methods of use |
| KR20220016865A9 (en) | 2019-05-15 | 2022-02-21 | 추가이 세이야쿠 가부시키가이샤 | Antigen Binding Molecules, Pharmaceutical Compositions, and Methods |
| IL297444A (en) * | 2020-04-20 | 2022-12-01 | Genzyme Corp | Humanized anti-complement factor bb antibodies and uses thereof |
| CN115427445A (en) * | 2020-04-22 | 2022-12-02 | 彻莫马布有限公司 | Methods of treatment using anti-CCL24 antibodies |
| EP4149486A1 (en) * | 2020-05-11 | 2023-03-22 | Genentech, Inc. | Complement component c1s inhibitors for treating a neurological disease, and related compositions, systems and methods of using same |
| EP4193153A1 (en) * | 2020-08-06 | 2023-06-14 | Bioverativ USA Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| EP4340879A4 (en) | 2021-05-20 | 2025-03-26 | Dianthus Therapeutics OpCo, Inc. | C1S-BINDING ANTIBODIES AND USES THEREOF |
| US11958899B2 (en) | 2021-07-13 | 2024-04-16 | Mabwell Therapeutics Inc. | Anti-C1s antibodies and uses thereof |
| AU2023293090A1 (en) | 2022-06-15 | 2025-01-30 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
| IL320903A (en) | 2022-11-21 | 2025-07-01 | Dianthus Therapeutics Opco Inc | Antibodies that bind to c1s and uses thereof |
| KR20250158063A (en) | 2023-03-16 | 2025-11-05 | 젠자임 코포레이션 | Treatment of dry age-related macular degeneration |
Family Cites Families (143)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| JPS60192263A (en) | 1984-03-13 | 1985-09-30 | Teijin Ltd | Standard material for measuring immunocomplex and masuring method of immunocomplex using said material |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| CA1276103C (en) | 1984-10-02 | 1990-11-13 | Fumiaki Taguchi | Substance-conjugated complement component c1q |
| JPS61271455A (en) | 1985-05-28 | 1986-12-01 | Olympus Optical Co Ltd | Immunological analysis |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| WO1988009344A1 (en) | 1987-05-21 | 1988-12-01 | Creative Biomolecules, Inc. | Targeted multifunctional proteins |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| EP0519596B1 (en) | 1991-05-17 | 2005-02-23 | Merck & Co. Inc. | A method for reducing the immunogenicity of antibody variable domains |
| CA2115742A1 (en) | 1991-08-20 | 1993-03-04 | Ronald G. Crystal | Adenovirus mediated transfer of genes to the gastrointestinal tract |
| EP0605522B1 (en) | 1991-09-23 | 1999-06-23 | Medical Research Council | Methods for the production of humanized antibodies |
| US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
| FR2688514A1 (en) | 1992-03-16 | 1993-09-17 | Centre Nat Rech Scient | Defective recombinant adenoviruses expressing cytokines and antitumour drugs containing them |
| JPH08503855A (en) | 1992-12-03 | 1996-04-30 | ジェンザイム・コーポレイション | Gene therapy for cystic fibrosis |
| CA2115811A1 (en) | 1993-02-17 | 1994-08-18 | Claus Krebber | A method for in vivo selection of ligand-binding proteins |
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| ATE212859T1 (en) | 1993-09-01 | 2002-02-15 | Sanquin Bloedvoorziening | C1 ESTERA INHIBITOR FOR REDUCING MYOCARDIAL DAMAGE DURING ACUTE HEART ATTACK |
| JP3875990B2 (en) | 1993-10-25 | 2007-01-31 | カンジ，インコーポレイテッド | Recombinant adenoviral vectors and methods of use |
| DK0796341T3 (en) | 1994-12-09 | 1999-06-14 | Imp College Innovations Ltd | Identification of genes that allow adaptation of a microorganism to a particular environment |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5968511A (en) | 1996-03-27 | 1999-10-19 | Genentech, Inc. | ErbB3 antibodies |
| CZ137399A3 (en) | 1996-10-17 | 1999-07-14 | Oxford Biomedica (Uk) Limited | Retroviral production system for producing replication defective vector particles |
| GB9621680D0 (en) | 1996-10-17 | 1996-12-11 | Oxford Biomedica Ltd | Lentiviral vectors |
| GB9622500D0 (en) | 1996-10-29 | 1997-01-08 | Oxford Biomedica Ltd | Therapeutic gene |
| US7083786B2 (en) | 1997-04-03 | 2006-08-01 | Jensenius Jens Chr | MASP-2, a complement-fixing enzyme, and uses for it |
| US6080849A (en) | 1997-09-10 | 2000-06-27 | Vion Pharmaceuticals, Inc. | Genetically modified tumor-targeted bacteria with reduced virulence |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| ATE412431T1 (en) | 1998-02-20 | 2008-11-15 | Tanox Inc | INHIBITORS OF COMPLEMENT ACTIVATION |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| EP1152759A2 (en) | 1999-02-09 | 2001-11-14 | 3-Dimensional Pharmaceuticals, Inc. | METHODS OF TREATING C1s-MEDIATED DISEASES AND CONDITIONS, AND COMPOUNDS AND COMPOSITIONS THEREFOR |
| AU4369000A (en) | 1999-04-26 | 2000-11-10 | Duke University | Inhibition of complement action |
| AU6929100A (en) | 1999-08-23 | 2001-03-19 | Biocrystal Limited | Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis |
| AU3099801A (en) | 2000-01-19 | 2001-07-31 | Biotransplant Incorporated | Swine defective for transmission of porcine endogenous retrovirus and uses thereof |
| DE60132169T2 (en) | 2000-01-31 | 2008-12-11 | Pharming Intellectual Property Bv | HUMAN C1 INHIBITOR MANUFACTURED IN THE MILK OF TRANSGENER MAMMALS |
| PT1265929E (en) | 2000-03-23 | 2009-10-15 | Genentech Inc | Anti-c2/c2a inhibitors of complement activation |
| AU2001282857A1 (en) | 2000-06-21 | 2002-01-02 | Zymogenetics Inc. | Peptide and polypeptide inhibitors of complement c1s |
| ES2649037T3 (en) | 2000-12-12 | 2018-01-09 | Medimmune, Llc | Molecules with prolonged half-lives, compositions and uses thereof |
| GB0105924D0 (en) | 2001-03-09 | 2001-04-25 | Microscience Ltd | Promoter |
| EP1416962A4 (en) | 2001-07-26 | 2006-05-24 | Alexion Pharma Inc | Method of improving cognitive function |
| EP1572893B1 (en) | 2001-11-09 | 2009-01-07 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY of the DEPARTMENT OF HEALTH AND HUMAN SERVICES | Production of adeno-associated virus in insect cells |
| JP2005515782A (en) | 2002-01-11 | 2005-06-02 | ジーティーシー バイオセラピューティックス インコーポレイテッド | Methods and systems for fusion and activation after transfer of nuclei to reconstructed embryos |
| US20080206242A1 (en) | 2002-03-01 | 2008-08-28 | Xencor, Inc. | Method of treatment of th2-mediated conditions using optimized anti-cd30 antibodies |
| US7657380B2 (en) | 2003-12-04 | 2010-02-02 | Xencor, Inc. | Methods of generating variant antibodies with increased host string content |
| SE0202880D0 (en) | 2002-07-26 | 2002-09-30 | Wieslab Ab | Complement system deficiency assay |
| US7666627B2 (en) | 2002-08-08 | 2010-02-23 | Targetex Kft. | Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| CA2496834C (en) | 2002-09-06 | 2014-03-18 | Alexion Pharmaceuticals, Inc. | Method of treatment of asthma using antibodies to complement component c5 |
| US7361339B2 (en) | 2003-01-09 | 2008-04-22 | Alexion Pharmaceuticals, Inc. | Methods for reducing morality associated with acute myocardial infarction |
| US9715692B1 (en) | 2003-04-11 | 2017-07-25 | Facebook, Inc. | System for managing bids for pay-per-click search engines |
| CN1787741B (en) | 2003-05-15 | 2011-08-17 | 唐纳士公司 | Methods and compositions for the prevention and treatment of sepsis |
| WO2005014849A2 (en) | 2003-07-03 | 2005-02-17 | Euro-Celtique, S.A. | Genes associated with responses to neuropathic pain |
| US7482376B2 (en) | 2003-07-03 | 2009-01-27 | 3-Dimensional Pharmaceuticals, Inc. | Conjugated complement cascade inhibitors |
| US8501705B2 (en) | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| WO2005025509A2 (en) | 2003-09-11 | 2005-03-24 | Board Of Regents, The University Of Texas System | Methods and materials for treating autoimmune diseases and conditions |
| WO2005035754A1 (en) | 2003-10-14 | 2005-04-21 | Chugai Seiyaku Kabushiki Kaisha | Double specific antibodies substituting for functional protein |
| US7803931B2 (en) | 2004-02-12 | 2010-09-28 | Archemix Corp. | Aptamer therapeutics useful in the treatment of complement-related disorders |
| CA2885854C (en) * | 2004-04-13 | 2017-02-21 | F. Hoffmann-La Roche Ag | Anti-p-selectin antibodies |
| US8840893B2 (en) | 2004-06-10 | 2014-09-23 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| US20060018896A1 (en) | 2004-06-10 | 2006-01-26 | University Of Leicester | Methods for treating conditions associated with lectin-dependent complement activation |
| US7919094B2 (en) | 2004-06-10 | 2011-04-05 | Omeros Corporation | Methods for treating conditions associated with MASP-2 dependent complement activation |
| CA2847677C (en) | 2004-06-10 | 2018-05-01 | Omeros Corporation | Methods for treating conditions associated with masp-2 dependent complement activation |
| CN102746404B (en) | 2004-11-12 | 2016-01-20 | 赞科股份有限公司 | To FcRn in conjunction with reformed Fc variant |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| EP1819731A4 (en) | 2004-12-08 | 2013-02-13 | Immunomedics Inc | Methods and compositions for immunotherapy and detection of inflammatory and immune-dysregulatory disease, infectious disease, pathologic angiogenesis and cancer |
| DE602006010834D1 (en) | 2005-03-16 | 2010-01-14 | Janssen Pharmaceutica Nv | NEW THIOPHENSULFOXIMINE FOR THE TREATMENT OF COMPLEMENTED DISEASES AND SUFFERING |
| ES2523666T3 (en) | 2005-05-31 | 2014-11-28 | Board Of Regents, The University Of Texas System | IgG1 antibodies with the mutated Fc part for increased binding to the FcRn receptor and uses thereof |
| CA2654440C (en) | 2005-06-06 | 2013-09-03 | Girish J. Kotwal | Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury |
| CN101218295B (en) | 2005-07-05 | 2010-12-08 | 株式会社钟化 | Methacrylic resin composition |
| US8124076B2 (en) | 2005-08-18 | 2012-02-28 | Ramot At Tel Aviv University Ltd. | Single chain antibodies against β-amyloid peptide |
| AU2006304804B2 (en) | 2005-10-21 | 2011-06-02 | Vertex Pharmaceuticals Incorporated | Modified proteases that inhibit complement activation |
| WO2007070375A2 (en) | 2005-12-09 | 2007-06-21 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| US9480658B2 (en) | 2005-12-09 | 2016-11-01 | The Board Of Trustees Of The Leland Stanford Junior University | Modulation of synaptic maintenance |
| PL1965831T3 (en) | 2005-12-21 | 2011-12-30 | Pharming Intellectual Property B V | Use of c1 inhibitor for the prevention of ischemia-reperfusion injury |
| FR2897868B1 (en) * | 2006-02-24 | 2012-08-31 | Lab Francais Du Fractionnement | ANTI-IDIOTYPIC ANTIBODIES THAT NEUTRALIZE THE INHIBITORY ACTIVITY OF AN INHIBITORY ANTIBODY DIRECTED AGAINST FIELD C1 OF FACTOR VIII. |
| AU2007223796B2 (en) | 2006-03-08 | 2013-01-24 | Astellas Us Llc | Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders |
| EP1989231B1 (en) | 2006-03-21 | 2015-05-20 | Genentech, Inc. | Combinatorial therapy involving alpha5beta1 antagonists |
| US8512981B2 (en) | 2006-06-21 | 2013-08-20 | Amsterdam Molecular Therapeutics B.V. | Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV |
| EP2061810B1 (en) | 2006-09-05 | 2014-11-12 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| CA3154415A1 (en) | 2006-10-10 | 2008-04-17 | Regenesance B.V. | Anti-sense oligonucleotide for use in facilitating axonal regeneration |
| US7858752B2 (en) | 2006-12-05 | 2010-12-28 | Abbott Laboratories | Recombinant antibodies against hepatitis C virus and methods of obtaining and using same |
| US8378138B2 (en) | 2006-12-19 | 2013-02-19 | The University of Hong Kong & Versitech Limited | Synthetic ion channels |
| DK2148691T3 (en) | 2007-02-05 | 2015-08-17 | Apellis Pharmaceuticals Inc | Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system |
| US8192742B2 (en) | 2007-03-23 | 2012-06-05 | NovelMed Therapeutics | Method of inhibiting complement activation with human anti-factor C3 antibodies and use thereof |
| RS53595B1 (en) | 2007-07-16 | 2015-02-27 | Genentech, Inc. | ANTI-CD79B ANTIBODIES AND IMMUNOCONCULATES AND METHODS OF USE |
| AU2008299779B2 (en) | 2007-08-03 | 2013-05-16 | Genentech, Inc. | Humanized anti-FGF19 antagonists and methods using same |
| WO2009020640A2 (en) * | 2007-08-08 | 2009-02-12 | Swarmcast, Inc. | Media player plug-in installation techniques |
| HRP20150279T1 (en) | 2007-12-26 | 2015-05-08 | Xencor, Inc. | Fc variants with altered binding to fcrn |
| WO2009121065A2 (en) | 2008-03-28 | 2009-10-01 | Apellis Ag | Modulation and repletion/enhancement of the complement system for treatment of trauma |
| WO2009132058A2 (en) | 2008-04-25 | 2009-10-29 | Zymogenetics, Inc. | Levels of bcma protein expression on b cells and use in diagnostic methods |
| CA2726845C (en) | 2008-06-04 | 2017-09-26 | Macrogenics, Inc. | Antibodies with altered binding to fcrn and methods of using same |
| US20090324585A1 (en) | 2008-06-12 | 2009-12-31 | The Trustees of the Leland Standford Junior University | Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis |
| BRPI0916668B1 (en) | 2008-08-05 | 2021-12-28 | Novartis Ag | ISOLATED MONOCLONAL ANTIBODY, PHARMACEUTICAL COMPOSITION, ISOLATED NUCLEIC ACID AND VECTOR |
| WO2010047830A2 (en) | 2008-10-24 | 2010-04-29 | The Scripps Research Institute | Agents for hcv treatment |
| CN109045296A (en) | 2008-11-10 | 2018-12-21 | 阿雷克森制药公司 | For treating the method and composition of complement associated disorders |
| JP5792626B2 (en) | 2008-12-01 | 2015-10-14 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | Methods and compositions for detection of complement fixation antibodies |
| AU2009324092A1 (en) * | 2008-12-03 | 2011-06-23 | Genmab A/S | Antibody variants having modifications in the constant region |
| US8401799B2 (en) | 2008-12-05 | 2013-03-19 | Lpath, Inc. | Antibody design using anti-lipid antibody crystal structures |
| US20100291106A1 (en) | 2009-05-06 | 2010-11-18 | Novartis Ag | Compositions and methods for antibodies targeting complement protein c3b |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| KR20120105405A (en) | 2009-06-23 | 2012-09-25 | 알렉시온 파마슈티칼스, 인코포레이티드 | Bispecific antibodies that bind to complement proteins |
| TW201117824A (en) | 2009-10-12 | 2011-06-01 | Amgen Inc | Use of IL-17 receptor a antigen binding proteins |
| DK2488203T3 (en) | 2009-10-16 | 2017-03-13 | Omeros Corp | METHODS OF TREATING DISSEMINATED INTRAVASCULAR COAGULATION BY INHIBITION OF MASP-2 DEPENDENT COMPLEMENT ACTIVATION |
| JP5851391B2 (en) | 2010-02-16 | 2016-02-03 | 国立大学法人京都工芸繊維大学 | Antibody-immobilized carrier, method for producing antibody-immobilized carrier, and use of the antibody-immobilized carrier |
| AU2011223866B2 (en) | 2010-03-01 | 2015-05-21 | Alexion Pharmaceuticals Inc. | Methods and compositions for treating Degos' disease |
| US9102949B2 (en) | 2010-04-23 | 2015-08-11 | University Of Massachusetts | CNS targeting AAV vectors and methods of use thereof |
| NZ629829A (en) | 2010-04-30 | 2015-11-27 | Alexion Pharma Inc | Anti-c5a antibodies and methods for using the antibodies |
| US9090674B2 (en) | 2010-05-17 | 2015-07-28 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
| MX2012014975A (en) | 2010-06-22 | 2013-03-12 | Univ Colorado Regents | Antibodies to the c3d fragment of complement component 3. |
| US9421240B2 (en) | 2010-06-22 | 2016-08-23 | Apellis Pharmaceuticals, Inc. | Compstatin analogs for treatment of neuropathic pain |
| TWI560199B (en) | 2010-08-31 | 2016-12-01 | Sanofi Sa | Peptide or peptide complex binding to α2 integrin and methods and uses involving the same |
| TW201241008A (en) | 2010-10-01 | 2012-10-16 | Alexion Pharma Inc | Polypeptides that bind to human complement component C5 |
| US8865164B2 (en) | 2010-11-02 | 2014-10-21 | Kypha, Inc. | Detecting complement activation |
| CA3211246A1 (en) | 2010-12-06 | 2012-06-14 | Seagen Inc. | Humanized antibodies to liv-1 and use of same to treat cancer |
| JP6147670B2 (en) | 2010-12-22 | 2017-06-14 | テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド | Modified antibodies with improved half-life |
| KR20220044616A (en) | 2011-04-08 | 2022-04-08 | 유니버시티 오브 레스터 | Methods for treating conditions associated with masp-2 dependent complement activation |
| CA2832871C (en) | 2011-05-04 | 2019-01-15 | Omeros Corporation | Compositions for inhibiting masp-2 dependent complement activation |
| US9289467B2 (en) | 2011-08-10 | 2016-03-22 | Case Western Reserve University | Compositions and methods for treating bone conditions |
| KR102022231B1 (en) | 2011-12-22 | 2019-09-19 | 체에스엘 베링 게엠베하 | Use of c1-inhibitor for the treatment of secondary edema of the central nervous system |
| JP6081699B2 (en) | 2011-12-28 | 2017-02-15 | 雅史 溝上 | Method for analyzing IL-28B |
| KR102041412B1 (en) | 2011-12-30 | 2019-11-11 | 한미사이언스 주식회사 | Derivatives of Immunglobulin Fc fragment |
| CN110818798A (en) | 2012-10-25 | 2020-02-21 | 美国比奥维拉迪维股份有限公司 | Anti-complement C1s antibodies and uses thereof |
| RS63212B1 (en) * | 2012-11-02 | 2022-06-30 | Bioverativ Usa Inc | ANTI-COMPLEMENT C1S ANTIBODIES AND THEIR APPLICATIONS |
| CN105143261B (en) * | 2013-01-31 | 2021-04-09 | 首尔大学校产学协力团 | C5 antibodies and methods for preventing and treating complement-related diseases |
| US20140294812A1 (en) | 2013-03-15 | 2014-10-02 | Xencor, Inc. | Fc variants that improve fcrn binding and/or increase antibody half-life |
| EP2996722A4 (en) | 2013-05-15 | 2017-01-11 | Annexon, Inc. | Methods of treatment for guillain-barre syndrome |
| PL3725803T3 (en) * | 2013-05-23 | 2022-04-04 | Broteio Pharma B.V. | Binding molecules that bind human complement factor c2b and uses thereof |
| SI3019240T1 (en) * | 2013-07-09 | 2024-07-31 | Annexon, Inc. | Anti-complement factor c1q antibodies and uses thereof |
| WO2015084999A1 (en) | 2013-12-06 | 2015-06-11 | True North Therapeutics, Inc. | Complement component biomarker assays |
| BR112017007393A2 (en) | 2014-10-18 | 2017-12-19 | Pfizer | anti-il-7r antibody compositions |
| HUE061076T2 (en) | 2015-04-06 | 2023-05-28 | Bioverativ Usa Inc | Application procedures for humanized anti-C1s antibodies |
| KR20180020296A (en) | 2015-06-26 | 2018-02-27 | 바이오버라티브 유에스에이 인코포레이티드 | How to treat autoimmune and allogeneic immune disorders |
| DK3525583T3 (en) | 2016-10-12 | 2025-10-27 | Bioverativ Usa Inc | ANTI-C1S ANTIBODIES AND METHODS OF USE THEREOF |
| TW202513092A (en) | 2017-03-14 | 2025-04-01 | 美商生物維瑞提夫美國公司 | Methods for treating complement-mediated diseases and disorders |
| JOP20190260A1 (en) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| KR20200143459A (en) | 2018-04-13 | 2020-12-23 | 추가이 세이야쿠 가부시키가이샤 | Anti-complement component antibodies and methods of use |
| WO2020081408A1 (en) | 2018-10-18 | 2020-04-23 | Merck Sharp & Dohme Corp. | Formulations of anti-rsv antibodies and methods of use thereof |
| EP4193153A1 (en) | 2020-08-06 | 2023-06-14 | Bioverativ USA Inc. | Inflammatory cytokines and fatigue in subject with a complement mediated disease |
| CN117241828A (en) | 2021-03-31 | 2023-12-15 | 美国比奥维拉迪维股份有限公司 | Reducing surgery-related hemolysis in patients with cold agglutinin disease |
| AU2023293090A1 (en) | 2022-06-15 | 2025-01-30 | Bioverativ Usa Inc. | Anti-complement c1s antibody formulation |
| WO2023250507A1 (en) | 2022-06-24 | 2023-12-28 | Bioverativ Usa Inc. | Methods for treating complement-mediated diseases |
-
2017
- 2017-10-12 DK DK17859451.1T patent/DK3525583T3/en active
- 2017-10-12 EP EP25188611.5A patent/EP4652926A2/en active Pending
- 2017-10-12 AR ARP170102855A patent/AR110677A1/en unknown
- 2017-10-12 HR HRP20251304TT patent/HRP20251304T1/en unknown
- 2017-10-12 IL IL308156A patent/IL308156A/en unknown
- 2017-10-12 TW TW111130089A patent/TWI846007B/en active
- 2017-10-12 TN TNP/2019/000109A patent/TN2019000109A1/en unknown
- 2017-10-12 US US16/340,991 patent/US20200048332A1/en not_active Abandoned
- 2017-10-12 MY MYPI2019001894A patent/MY198182A/en unknown
- 2017-10-12 SG SG11201903012RA patent/SG11201903012RA/en unknown
- 2017-10-12 KR KR1020197013448A patent/KR102638884B1/en active Active
- 2017-10-12 PT PT178594511T patent/PT3525583T/en unknown
- 2017-10-12 ES ES17859451T patent/ES3049257T3/en active Active
- 2017-10-12 CA CA3040253A patent/CA3040253A1/en active Pending
- 2017-10-12 TW TW106134895A patent/TWI773695B/en active
- 2017-10-12 JP JP2019519690A patent/JP7069138B2/en active Active
- 2017-10-12 WO PCT/US2017/056349 patent/WO2018071676A1/en not_active Ceased
- 2017-10-12 CN CN201780074920.XA patent/CN110300520B/en active Active
- 2017-10-12 LT LTEPPCT/US2017/056349T patent/LT3525583T/en unknown
- 2017-10-12 CN CN202211195613.6A patent/CN116554320A/en active Pending
- 2017-10-12 EP EP17859451.1A patent/EP3525583B8/en active Active
- 2017-10-12 RS RS20251039A patent/RS67326B1/en unknown
- 2017-10-12 BR BR112019007309A patent/BR112019007309A2/en unknown
- 2017-10-12 CR CR20190223A patent/CR20190223A/en unknown
- 2017-10-12 FI FIEP17859451.1T patent/FI3525583T3/en active
- 2017-10-12 EA EA201990884A patent/EA201990884A1/en unknown
- 2017-10-12 KR KR1020247005368A patent/KR102891406B1/en active Active
- 2017-10-12 PE PE2019000814A patent/PE20191031A1/en unknown
- 2017-10-12 IL IL265957A patent/IL265957B2/en unknown
- 2017-10-12 AU AU2017341766A patent/AU2017341766A1/en not_active Abandoned
- 2017-10-12 MX MX2019004259A patent/MX2019004259A/en unknown
- 2017-10-12 TW TW113117929A patent/TW202434298A/en unknown
-
2019
- 2019-04-08 DO DO2019000085A patent/DOP2019000085A/en unknown
- 2019-04-10 ZA ZA2019/02247A patent/ZA201902247B/en unknown
- 2019-04-11 CL CL2019000975A patent/CL2019000975A1/en unknown
- 2019-04-11 PH PH12019500789A patent/PH12019500789A1/en unknown
- 2019-04-11 MX MX2024008202A patent/MX2024008202A/en unknown
- 2019-05-08 CO CONC2019/0004741A patent/CO2019004741A2/en unknown
- 2019-05-10 EC ECSENADI201933211A patent/ECSP19033211A/en unknown
-
2022
- 2022-04-28 JP JP2022073972A patent/JP7420864B2/en active Active
- 2022-07-12 AU AU2022205174A patent/AU2022205174B2/en active Active
-
2023
- 2023-07-07 US US18/349,027 patent/US12391750B2/en active Active
-
2024
- 2024-01-11 JP JP2024002216A patent/JP2024038319A/en not_active Withdrawn
-
2025
- 2025-11-13 AU AU2025267421A patent/AU2025267421A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201903012RA (en) | Anti-c1s antibodies and methods of use thereof | |
| SG11201908396PA (en) | Methods of treating tumor | |
| SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
| SG11201807252QA (en) | Anti-lag-3 antibodies | |
| SG11201804161VA (en) | Compositions comprising bacterial strains | |
| SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201805072PA (en) | Nicotine powder delivery system | |
| SG11201807279QA (en) | Binding proteins and methods of use thereof | |
| SG11201804162WA (en) | Compositions comprising bacterial strains | |
| SG11201810429UA (en) | Anti-cd19 antibody formulations | |
| SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
| SG11201907583TA (en) | Methods for treating complement-mediated diseases and disorders | |
| SG11201806845VA (en) | Moisturizing compositions and uses thereof | |
| SG11201806398YA (en) | Optimized factor viii genes | |
| SG11201907208XA (en) | Radiolabeled anti-lag3 antibodies for immuno-pet imaging | |
| SG11201809499UA (en) | Processes for preparing phosphorodiamidate morpholino oligomers | |
| SG11201805204WA (en) | Nicotine particle capsule | |
| SG11201809531SA (en) | BINDING MOLECULES SPECIFIC FOR FCγGAMMA RIIA AND USES THEREOF | |
| SG11201900132QA (en) | Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy | |
| SG11201808525UA (en) | Anti-complement factor bb antibodies and uses thereof | |
| SG11201809594WA (en) | Nicotine particles and compositions | |
| SG11202000333UA (en) | Bicyclic ketone compounds and methods of use thereof | |
| SG11201807549TA (en) | Combination of a cxcr4 antagonist and an immune checkpoint inhibitor | |
| SG11201908918WA (en) | Novel pyridazinone herbicides |